Financial Review: Arrowhead Pharmaceuticals (NASDAQ:ARWR) & Pliant Therapeutics (NASDAQ:PLRX)

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Pliant Therapeutics and Arrowhead Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pliant Therapeutics N/A -52.17% -40.46%
Arrowhead Pharmaceuticals -47.79% -60.06% -17.37%

Analyst Recommendations

This is a summary of current ratings and target prices for Pliant Therapeutics and Arrowhead Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pliant Therapeutics 1 1 1 0 2.00
Arrowhead Pharmaceuticals 1 3 10 1 2.73

Pliant Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 305.41%. Arrowhead Pharmaceuticals has a consensus target price of $99.07, suggesting a potential upside of 110.12%. Given Pliant Therapeutics’ higher probable upside, equities research analysts plainly believe Pliant Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Risk and Volatility

Pliant Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Institutional & Insider Ownership

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Pliant Therapeutics and Arrowhead Pharmaceuticals”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pliant Therapeutics $1.58 million 29.00 -$149.34 million ($1.49) -0.50
Arrowhead Pharmaceuticals $829.45 million 8.01 -$1.63 million ($2.25) -20.96

Arrowhead Pharmaceuticals has higher revenue and earnings than Pliant Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Pliant Therapeutics beats Arrowhead Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Pliant Therapeutics

(Get Free Report)

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver. Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins αvβ1 and αvβ6.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.